Trial Profile
A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living With HIV-1
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; VRC 01LS (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACTG A5357
- 06 Mar 2024 Results assessing safety and efficacy of VRC07-523LS Plus Long-Acting Cabotegravir, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 28 Feb 2024 According to a GSK media release, efficacy and safety data from this study will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) being held in Denver, Colorado, from 3-6 March 2024.
- 22 Mar 2023 Planned primary completion date changed from 30 May 2023 to 30 May 2024.